Want to see NAGE full AI Analyst Report?
NAGE Stock Chart & Stats
$3.21
$0.02(0.62%)
At close: 4:00 PM EDT
$3.21
$0.02(0.62%)
Day’s Range― - ―
52-Week Range$2.87 - $10.52
Previous Close$3.25
Volume413.05K
Average Volume (3M)702.29K
Market Cap
$241.33M
Enterprise Value$198.78
Total Cash (Recent Filing)$66.74M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)15.2
Beta0.95
Next Earnings
Nov 04, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding79,126,000
10 Day Avg. Volume757,578
30 Day Avg. Volume702,286
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.58
Price to Sales (P/S)3.89
P/FCF Ratio38.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.20Price Target Upside217.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.15
Revenue Forecast (FY)$134.14M
Bulls Say, Bears Say
Bulls Say
Stable, High Gross MarginsConsistently high gross margins in the low-to-mid 60% range provide durable earnings power, supporting reinvestment in R&D, marketing, and product launches. Margin stability cushions profitability through competitive pressure and funds strategic initiatives without immediate reliance on external financing.
Conservative Balance Sheet, No DebtA very low-leverage balance sheet and sizable cash position give the company financial flexibility to fund new product rollouts, telehealth/pharma investments, and buybacks while absorbing cyclical pressures. This reduces solvency risk and permits strategic choices without dilutive capital raises.
Direct-to-consumer E‑commerce StrengthStrong, repeatable DTC/e‑commerce growth builds customer relationships, higher lifetime value, and lower reliance on volatile wholesale orders. Coupled with product/telehealth launches and expanded retail distribution, this channel diversification supports sustainable revenue and marketing efficiency over multiple quarters.
Bears Say
Inconsistent Cash ConversionTTM operating cash flow lagging net income and prior-period cash burn indicate working-capital timing and inventory risks. Inconsistent cash conversion weakens the reliability of reported earnings to fund recurring investments, dividends, or buybacks and raises sensitivity to partner/payment timing shocks.
Weak Revenue MomentumFlattening revenue despite margin recovery suggests demand normalization and reliance on a few growth drivers. Sustaining guidance will require successful product rollouts and channel expansion; persistent top-line stagnation would strain the company’s ability to scale fixed costs and justify elevated marketing and R&D investments.
Regulatory And NMN Competitive HeadwindsRegulatory uncertainty and a surge of NMN competitors create structural category risk: increased pricing pressure, higher customer-acquisition costs, and potential market share loss. Ongoing litigation adds a binary legal risk that could materially reshape long-term addressable market dynamics and corporate strategy.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience, Inc.’s price range in the past 12 months?
Niagen Bioscience, Inc. lowest stock price was $2.87 and its highest was $10.52 in the past 12 months.
What is Niagen Bioscience, Inc.’s market cap?
Niagen Bioscience, Inc.’s market cap is $241.33M.
When is Niagen Bioscience, Inc.’s upcoming earnings report date?
Niagen Bioscience, Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 81 days.
How were Niagen Bioscience, Inc.’s earnings last quarter?
Niagen Bioscience, Inc. released its earnings results on Aug 04, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.002.
Is Niagen Bioscience, Inc. overvalued?
According to Wall Street analysts Niagen Bioscience, Inc.’s price is currently Undervalued.
Does Niagen Bioscience, Inc. pay dividends?
Niagen Bioscience, Inc. does not currently pay dividends.
What is Niagen Bioscience, Inc.’s EPS estimate?
Niagen Bioscience, Inc.’s EPS estimate is 0.02.
How many shares outstanding does Niagen Bioscience, Inc. have?
Niagen Bioscience, Inc. has 79,126,000 shares outstanding.
What happened to Niagen Bioscience, Inc.’s price movement after its last earnings report?
Niagen Bioscience, Inc. reported an EPS of $0.01 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went down -14.697%.
Which hedge fund is a major shareholder of Niagen Bioscience, Inc.?
Currently, no hedge funds are holding shares in NAGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.20 (217.76% Upside)
$10.20 (217.76% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 86.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.46%
Trailing 12-Months
Company Description
Niagen Bioscience, Inc.
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.
NAGE Company Deck
NAGE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone: solid revenue and net income, strong e-commerce growth, margin stability, a robust cash position, and several strategic wins (USP monograph, new product launches, scientific leadership). Offsetting items include short-term cash flow drag from inventory and timing, higher selling/marketing and G&A investments, channel volatility with some distribution partners, and intensified competition and regulatory uncertainty around NMN which is creating headwinds. Management reaffirmed full-year guidance (10%–15% growth) while electing to invest in marketing and product rollouts to drive future growth.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$10.20
▲(217.76% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Vir Biotechnology
―
Fortrea Holdings Inc.
―
Septerna, Inc.
―
Ownership Overview
5.07% Insiders
7.91% Mutual Funds
4.62% Other Institutional Investors
74.20% Public Companies and
Individual Investors